John Ridden, Blueberry CEO will be attending BIO International convention in Boston, 4th-7th June. 2018 is the 25th year for the BIO Convention, and attracts more than 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships.
John Ridden, David Cook and Mark Hollingworth will be attending BioTrinity London 23-25 April. BioTrinity is Europe’s leading biopartnering and investment conference, and is in its 12thconsecutive year. The theme for 2018 is “Next Generation Healthcare”. We look forward to seeing you there!
David presented at a recent Oxford Bio Network (OBN) BioTuesday Seminar, “De-risking the Valley of Death – How R&D Companies can access the Knowledge Network to Maximise Success” as part of a delegation from the BioHub at Alderley Park. The seminar’s focus was on how collaboration and working together can help cross the drug development “Valley of Death”. David’s presentation focused on how Blueberry has built an extensive network of collaborations to bring in expertise and help them progress their lead anti-fungal programme to clinical testing in a very cost effective and efficient way.
8th -11th of January 2018: CEO Dr. John Ridden has been invited to attend the J.P. Morgan 36th Annual Healthcare Conference in San Francisco, California. John will be presenting Blueberry to a number of prospective investors at this conference.
Blueberry Therapeutics CSO David Cook presents at the first Royal Society Creating Connections conference, Research, industry and infrastructure in the North West, at Manchester’s Museum of Science and Industry. David was invited to speak at this exciting event, which brought together academics, industry experts and policy makers, to discuss a range of topics including Human Health, Materials, and Data. David presented in the Human health session.
John Ridden, CEO of Blueberry Therapeutics, recently presented at the UK-China Life Science Event run by the DIT (Department for International Trade). The event was hosted by Lancaster University and is an opportunity for Life Science companies in the Northern Powerhouse to network and pitch to Chinese companies and investors.
Blueberry Therapeutics Ltd is pleased to announce that it has taken a significant step forward in the development of new Acne treatments by gaining support from Innovate UK to co-fund critical research of this exciting programme. Principal Scientist Christine Ridden said “Thanks to the support from Innovate UK we will be able to rapidly asses the feasibility of a range of new topical nanomedicnes for the treatment of acne. If successful, these new medicines will represent a step forward in acne treatment with dual action therapies that tackle the symptoms of acne whilst preventing disease progression”. This is another important step in building our pipeline and follows the entry of our lead product, BB2603 for Onychomycosis, into clinical trials earlier this year.
Blueberry Therapeutics Ltd. is a modern drug discovery and development company which is focused on treating infectious dermatological disorders in the short term, and addressing the global problem of antibiotic resistance in the long term. Blueberry employs state of the art technologies including nanotechnology based topical delivery systems and biologic and small molecule lead platforms to generate potent selective and safe molecules (peptides, antibodies, small molecules) for clinical development into new effective treatments to benefit patients. By focusing on well validated drug targets and ensuring our candidate molecules have a very low toxicity liability, we believe we can mitigate or even avoid two of the major reasons for drug failures in the clinic.
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow […]
Blueberry Therapeutics CEO John Ridden presented at the Biofocus 2017 event at the Centre for Life in Newcastle upon Tyne as part of the Industry Showcase session. The Biofocus event is an annual event bringing together industry academia and experts within the field of life sciences.
Blueberry Scientists Sarah Main and Julie Cook, attended the “Kinetics, Binding and Biophysics in Drug Discovery” workshop at The Mechanics Centre, Manchester on 27th June 2017. Attending the workshop will assist in current and future assay development in our antibiotic resistance research programs.
CSO David Cook attended the European Mediscience Awards Dinner in London as a guest of Zeus Capital. The Mediscience Awards recognize excellence in the Life Science sector and are held annually.
CSO David Cook presented at the recent ELRIG (European Laboratory Research & Innovation Group) held at Alderley Park.
David presented as part of a diverse evening of seminars on the topic “Novel Approaches to Meeting the Challenges of Antimicrobial Drug Resistance”, and talked about Blueberry’s long-term ambitions in developing new treatments for infection.
Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals. The trial, which is a safety and efficacy study in onychomycosis (fungal nail infection and associated tinea pedis (athlete’s foot), began on March 28th 2017, with primary and secondary endpoints expected to read out during the second half of this year.
BB2603 is an innovative new treatment concept using nanotechnology to deliver terbinafine, a potent antifungal, through the nail and into skin to treat fungal infection. This novel patented nanomedicine will initially be used to treat onychomycosis which is a highly infectious disease with a high medical need that is currently poorly managed by current treatments
Dr Mike Davies, Chief Medical Officer and Co-founder of Blueberry Therapeutics, said, “This is a great achievement by the team at Blueberry that has led to approvals and the start of our first clinical trial with BB2603 – our exciting, novel nanoformulation of terbinafine to treat onychomycosis and associated tinea pedis”
Progression of the lead product into the clinic has been a major step forward for Blueberry in the development of its lead topical anti-fungal. The resultant data will be used to support the opening of an Investigational New Drug Application in the US later this year in the United States.
John Ridden, CEO of Blueberry Therapeutics said, ‘This is an exciting time for Blueberry – we are making excellent headway in clinical development of BB2603 to establish its effectiveness in treating onychomycosis and […]
David gave a presentation to Manchester Metropolitan University as part of their Biomedical Away Day.
His presentation was on the Opportunities and Challenges in collaborating between Universities and Industry.
Mike Davies, CMO and Co-founder, presented at the SMI Conference “Adaptive Designs in Clinical Trials” in London on 4th April 2017.
In it, Mike described how Blueberry Therapeutics utilises adaptive clinical trial designs for its lead compound, BB2603, a novel nanoparticle formulation of terbinafine, to treat onychomycosis and tinea pedis.
Blueberry’s CEO John Ridden was interviewed by Times writer Michael Cape.
John and Michael spoke about how Blueberry benefitted from AstraZeneca’s move to Cambridge, which led to husband and wife team David and Julie Cook (CSO and Principal Scientist) joining Blueberry in 2014.
Read the article here:
http://www.supernorth.co.uk/wp-content/uploads/2017/03/Super-North_170316-4.pdf
Julie Cook, one half of the husband and wife team, said “Although David and I both worked for AstraZeneca for a number of years, we have always worked in different departments. This is the first time we’ve worked closely together professionally. It’s great to be doing that in a small, exciting company”.
The Blueberry Clinical Team, consisting of Dr Mike Davies, co-founder and Chief Medical Officer, Mark Sidaway, Clinical Project Manager and Jane Davies, Senior CRA, held their site initiation visit (SIV) at the Parexel Early Phase Clinical Unit in Berlin, Germany on Wednesday 8 March 2017. This is in preparation for Blueberry’s first clinical trial with our novel, topical spray formulation of terbinafine to treat onychomycosis and associated tinea pedis. This first trial of BB2603 will look at the safety, local toleration, systemic and local pharmacokinetics as well as efficacy in the chronic and frequently recurrent conditions of onychomycosis and tinea pedis. Onychomycosis is currently treated with either oral antifungals (that have safety and systemic toleration issues), or topically applied antifungals and other medicines that show a very low efficacy.
The first trial of BB2603 is predicted to start in the coming weeks and will deliver primary and secondary endpoints, reading out mid 2017.
Dr. med. Rainard Fuhr (Investigator) and Dr Tommaso Fadini (Co-Investigator) examine the nail sampling instrumentation
Examining the contents of the Blueberry cupboard at the Parexel EPCU
The Blueberry BB2603 clinic room
Jane Davies (Snr CRA), Dr. med. Rainard Fuhr (Investigator), Mark Sidaway (CPM), Dr Tommaso Fadini (Co-Investigator) and Sabine Klein-Haggerty (SCRC) at the […]